Placebo + RO5093151
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD
Conditions
Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD
Trial Timeline
Apr 1, 2011 → Mar 1, 2012
NCT ID
NCT01277094About Placebo + RO5093151
Placebo + RO5093151 is a phase 1 stage product being developed by Roche for Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD. The current trial status is completed. This product is registered under clinical trial identifier NCT01277094. Target conditions include Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01493271 | Phase 2 | Completed |
| NCT01277094 | Phase 1 | Completed |
Competing Products
20 competing products in Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lanifibranor | Inventiva | Phase 2 | 47 |
| Low Dose REN001 + High Dose REN001 | OnKure Therapeutics | Phase 1 | 25 |
| GODEX + Placebo | Celltrion | Phase 3 | 77 |
| placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo | AstraZeneca | Phase 2 | 52 |
| AZ compound | AstraZeneca | Phase 2 | 52 |
| Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD7503 Intervention | AstraZeneca | Phase 1 | 33 |
| metformin | Merck | Phase 2/3 | 65 |
| Efinopegdutide + Semaglutide + Placebo | Merck | Phase 2 | 52 |
| MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochloride | Merck | Phase 1 | 33 |
| Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL | Merck | Phase 2 | 52 |
| LYS006 + Tropifexor | Novartis | Phase 2 | 52 |
| LJN452 | Novartis | Phase 1 | 33 |
| LCQ908 + placebo | Novartis | Phase 2 | 52 |
| Orlistat (Xenical) | Roche | Approved | 85 |
| Xenical, Pegasys, Copegus | Roche | Approved | 85 |
| AMG 609 + Placebo | Amgen | Phase 1 | 32 |
| Glucagon | Novo Nordisk | Pre-clinical | 22 |
| Blood samples | Novo Nordisk | Pre-clinical | 22 |
| NNC0194-0499 + NNC0194-0499 + NC0194-0499 | Novo Nordisk | Phase 1 | 32 |